您的位置>>首页 > 师资队伍
师资队伍
郭颖杰
基本情况
姓名: 郭颖杰
性别:
职称: 教授
是否博导:
最高学历: 研究生
最高学位: 博士
电话:
Email:
详细情况
所研究方向: 1) 遗传药理学研究;2) 基因多态性对蛋白结构和功能的影响;
讲授课程: 药理学;药理学实验
教育经历: 1989.9 ~1993.7 沈阳药科大学药剂专业 获学士学位
1998.9 ~2001.7 长春中医学院药理专业 获硕士学位
1998.10~2000.10 日本北里大学东洋医学研究所 交流学习
2002.9 ~2005.7 吉林大学生化和分子生物学专业 获博士学位
工作经历: 1993.7~1995.12 吉林省中医中药研究院药理研究室 初级研习员
1996.1~2002.7 吉林省中医学院附属医院新药开发中心 初级研习员
2005.7~2008.8 吉林大学生命科学学院 讲师
2008.9~至今 吉林大学生命科学学院 副教授
科研项目: 1)国家自然科学基金:31071105 转甲状腺素蛋白Val30Ala 突变在家族型淀粉样多神经病中的作用机制研究。2011年-2013年,34万元,负责人。
2) 国家自然科学基金31271477: CHK1介导组蛋白去乙酰化酶抑制剂协同化疗药物杀伤AML细胞的机理研究。2013年-2016年, 80万元,主要成员。
3)“重大新药创制”国家科技重大专项课题:2009ZX09304-003临床前药物代谢动力学技术平台。 2009-2010年,330万元,主要成员。
4)国家自然科学基金:30472062 CYP2C9新突变体的结构与功能研究。2005年-2007年,21万元,主要成员。
学术论文: 发表的部分相关论文:
1)Zhang F, Hu C, Dong Y, Lin MS, Liu J, Jiang X, Ge Y, Guo Y.The impact of V30A mutation on transthyretin protein structural stability and cytotoxicity against neuroblastoma cells. Arch Biochem Biophys. 2013 Mar 22;535(2):120-127.
2) Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, Sun L, He Y, Ge Y, Yu Q.Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochem Biophys Res Commun. 2013 Apr 26;434(1):95-101.
3)Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y.Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One. 2012;7(12):e52095.
4)Guo Mingyi; Wang Aifei; Muhammad, Faheem; Qi Wenxiu; Ren Hao; Guo Yingjie*; Zhu Guangshan*. Halloysite Nanotubes, a Multifunctional Nanovehicle for Anticancer Drug Delivery.CHINESE JOURNAL OF CHEMISTRY. 2012,30:2115-2120.
5)Guo, Yingjie; Hu, Cheng; He, Xiaojing; Qiu, Feng; Zhao, Limei*.Effects of UGT1A6, UGT2B7, and CYP2C9 Genotypes on Plasma Concentrations of Valproic Acid in Chinese Children with Epilepsy. DRUG METABOLISM AND PHARMACOKINETICS, 2012,27:536-542.
6)Guo Y, Xu X, Qi W, Xie C, Wang G, Zhang A, Ge Y.Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines. Mol Med Report. 2012 Mar;5(3):734-8.
7)Muharnmad, F; Guo, MY; Qi, WX ; Sun, FX ; Wang, AF ; Guo, YJ *; Zhu, GS *. 2pH-Triggered Controlled Drug Release from Mesoporous Silica Nanoparticles via Intracelluar Dissolution of ZnO Nanolids. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2011,133(23): 8778-8781.
8)Liu, JY ; Guo, YJ; Zhou, CK ; Ye, YQ ; Feng, JQ ; Yin, F ; Jiang, XM . Clinical and histopathological features of familial amyloidotic polyneuropathy with transthyretin Val30Ala in a Chinese family. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011,: 304(1-2): 83-86.
9)Meng, HM; Guo, GM ; Ren, JY; Zhou, H; Ge, YB ; Guo, YJ *. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. EPILEPSY & BEHAVIOR, 2011,21(1): 27-30.
10) Meng, HM; Ren, JY; Lv, YD; Lin, WH*; Guo, YJ*. Association study of CYP3A5 genetic polymorphism with serum concentrations of carbamazepine in Chinese epilepsy patients. NEUROLOGY ASIA, 2011, 16(1): 39-45.
11) Muhammad, F ; Guo, MY; Guo, YJ; Qi, WX; Qu, FY; Sun, FX; Zhao, HJ; Zhu, GS. Acid degradable ZnO quantum dots as a platform for targeted delivery of an anticancer drug. JOURNAL OF MATERIALS CHEMISTRY, 2011, 21(35): 13406-13412.
12)Dayong Si, Ying Wang, Yi-Han Zhou, Yingjie Guo, Juan Wang, Hui Zhou*, Ze-Sheng Li, and J. Paul Fawcett. Mechanism of CYP2C9 Inhibition by Flavones and Flavonols Drug Metabolism and Disposition 2009 37: 629-634.
13)Ying Wang, Yihan Zhou, Yingjie Guo , Xuelian Xu, Dayong Si, Hui Zhou, Zesheng Li.Role of Residue 90 in Catalysis of Cytochrome P450 2C9 Chemical Research in Chinese Universities 2009, 25(6) 904-908.
14) Yan T, Li H, Deng L, Yingjie Guo, Yu W, Fawcett JP, Zhang D, Cui Y, Gu J. Liquid chromatographic–tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma. J Pharm Biomed Anal. 2008;28:1225-1229.
15)Yifan Zhang, Dayong Si, Xiaoyan Chen, Nan Lin, Yingjie Guo, Hui Zhou, Dafang Zhong. Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. The British Journal of Clinical Pharmacology, 2007,64(1):67-74.
16) Zhou Yihan; Zheng Qingchuan; Li Zesheng*; Zhang Yuan; Sun Miao; Sun Chia-Chung;Si Dayong; Cai Lei; Guo Yingjie; Zhou Hui*, On the human CYP2C9 variant *13 activity reduction: a molecular, dynamics simulation and docking study. Biochimie, 2006 88(10):1457-1465.
17) Yingjie Guo, Yifan zhang, Ying Wang, Xiaoyan Chen, Dayong Si, Dafang zhong, J Paul Fawcett and Hui Zhou. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in human. Drug Metabolism and Disposition. 2005;59:14-17.
18).Yingjie Guo, Ying Wang, Dayong Si, Paul J. Fawcett, Dafang Zhong, Hui Zhou. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica. 2005; 35:853-861.
19).Yingjie Guo, Tsukasa Matumto, Yuki Kikuchi et al. Effect of a pectic polysaccharide from a medicinal herb, oots of bupleurum falcatum L. on interleukin 6 production of murine B clls and B cells lines. Immunopharmacology. 2000, 49:307-316.
20).Matsumoto T, Hosono-Nishiyama K, Yingjie Guo, Ikejima T, Yamada H. A possible signal transduction pathway for cyclin D2 expression by a pectic polysaccharide from the roots of bupleurum falcatum L. in murine B cell. Int Immunopharmacol. 2005; 5:1373-86.
21).Dayong Si, Yingjie Guo, Yifan Zhang, Lei Yang, Hui Zhou and Dafang Zhong Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004;14:465-469.
22).Tsukasa Matsumoto, Yingjie Guo, Takashi Ikejima, Haruki Yamada. Induction of cell cycle regulatory proteins by murine B cell proliferating pectic polysaccharide from the roots of Bupleurum falcatum L. Immunology Letters 2003;89: 111-118.

版权所有:吉林大学生命科学学院 2017 © 电话:+(86)-431-81969061

地址:吉林省长春市前进大街2699号生命科学楼 邮编:130012   Power by leeyc